According to a new study published ahead-of-print in the Journal of Thoracic and Cardiovascular Surgery, St Jude Medical’s Trifecta aortic valve has a similar haemodynamic performance to that of a healthy aortic valve and is “easy to implant”.
Abbott Vascular has announced that the FDA Circulatory System Devices Panel of the Medical Devices Advisory Committee has voted five to three that the benefits of its MitraClip system for the management of mitral regurgitation outweigh its risks. However, the panel also voted five to four that there was not a reasonable assurance of the device’s efficacy.
Boston Scientific has announced that the Platinum China study, which was presented at China Interventional Therapeutics (20–23 March, Beijing, China), indicated that the Promus Element stent is associated with a low rate of stent thrombosis at nine months. These data support the existing safety and efficacy data for the stent.
Pero se necesita más investigación sobre las bebidas ricas en cafeína, según una revisión
Los resultados sorprenden y decepcionan a los científicos
Los resultados del procedimiento coronario que no es de emergencia fueron similares entre los hospitales en un estudio de Massachusetts
Of relevance to the clinical practice of interventional cardiology, Medtronic, Inc. (NYSE: MDT) announced today that it has received regulatory approval to update the CE (Conformité Européenne) mark labeling for the Resolute Integrity drug-eluting stent with new information on one month of dual antiplatelet therapy (DAPT), the shortest minimum duration referenced on the label for any device of its kind.
Medtronic has announced that it has approval to update the CE mark dual antiplatelet therapy (DAPT) labelling for its drug-eluting Resolute Integrity stent, meaning that DAPT can be discontinued or interrupted after one month.
Boston Scientific Corporation (NYSE: BSX) is scheduled to present sponsored research at the 62nd Annual Scientific Session of the American College of Cardiology which takes place March 9-11 in San Francisco, California. The clinical presentations will provide new insights on Boston Scientific research in cardiovascular disease, including aortic valve disease and atrial fibrillation.
The UK’s National Institute for Health and Clinical Excellence (NICE) has published the draft version of its guidance for the acute management of ST-segment-elevation myocardial infarction (STEMI) as part of its public consultation process The timeliness of primary percutaneous coronary intervention (PPCI) forms a key part of the draft guideline so commissioners and those delivering services for people with STEMI can plan their configuration in such a way that outcomes are optimal. This guideline also covers the use of antiplatelet and antithrombin agents, and improving outcomes for the minority of people still receiving fibrinolysis.
Un estudio halla que los estilos de vida saludables protegen doblemente contra dos importantes grupos de enfermedades
Medtronic has announced that, following CE mark approval, its Engager transcatheter aortic valve implantation (TAVI) system can now be used in patients with severe aortic stenosis who are high or extreme risk of surgery.
Medtronic, Inc. (NYSE: MDT) today announced CE (Conformité Européenne) Mark of the Engager Transcatheter Aortic Valve Implantation (TAVI) System with transapical delivery catheter to treat patients with severe aortic stenosis who are at high or extreme risk for surgical aortic valve replacement (SAVR).
BioFreedom represents the latest development in Biosensors stent technology, featuring a micro-structured abluminal surface which permits the controlled release of Biolimus A9™ (BA9™) without the use of a polymer. BA9 is a highly lipophilic anti-restenotic drug developed by Biosensors specifically for use with stents.
On 12 February 2013, Boston Scientific received CE mark approval for its Promus Premier Everolimus-Eluting Platinum Chromium Coronary Stent System, the company’s next-generation durable polymer drug-eluting stent technology, and has begun its European market launch. According to a company release, the Promus Premier Stent System is designed to provide physicians improved drug-eluting stent performance in treating patients with coronary artery disease. It is the only platform to feature a customised Platinum Chromium stent architecture, the market-leading Everolimus drug coating and fluorinated co-polymer, and an enhanced stent delivery system.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos